Study Details
BAX 111 rVWF in Pediatrics
(IRB#: IRB_00099444)
The purpose of the study is to look at how well recombinant von Willebrand Factor (rVWF) (the study drug) works to control bleeding that is not caused by surgery. The study will involve children with severe von Willebrand disease (VWD), and we hope to learn how safe the study drug is and how well it is accepted. The study will also look at how safe the study drug is and how well it works during surgery. Finally, the study will look at how childrens bodies process the study drug. This is a Phase 3 study, which means the study drug has already been given to other patients in other studies. In a Phase 3 study the new drug is tested longer and on more people.
- All genders
- Under 18 years old
- Volunteers with special conditions
- In Person
- Paid
Who can participate?
Gender: All genders
Age: Under 18 years old
Volunteers: Volunteers with special conditions
Location: In Person
Inclusion Criteria
- Diagnosis of severe VWD (defined as VWF:RCo <20%): a. Type 1 (VWF:RCo <20 IU/dL); or b. Type 2A (VWF:RCo <20 IU/dL), Type 2B (as diagnosed by genotype), Type 2N (FVIII:C <10% and historically documented genetics), Type 2M; or c. Type 3 (VWF:Ag 3 IU/dL).
Will I be paid for my time?
Yes
IRB#: IRB_00099444
PI: Jessica Meznarich
Department: PEDIATRIC HEMATOLOGY/ONCOLOGY
Approval Date: 2017-07-05 06:00:00
Specialties: Pediatric Hematology & Oncology